Prevalence of Antiphospholipid Syndrome Up for Roma SLE

This article originally appeared here.
Share this content:
Prevalence of Antiphospholipid Syndrome Up for Roma SLE
Prevalence of Antiphospholipid Syndrome Up for Roma SLE

WEDNESDAY, June 14, 2017 (HealthDay News) -- The prevalence and risk of antiphospholipid syndrome (APS) is higher for Roma versus Caucasian systemic lupus erythematosus (SLE) patients, according to a study published online June 7 in the International Journal of Rheumatic Diseases.

Victoria Manzano-Gamero, from the Complejo Hospitalario Universitario de Granada in Spain, and colleagues conducted a cross-sectional study including data from 52 Roma and 98 Caucasian SLE patients consecutively attending six hospitals in Spain. The authors compared socio-demographic characteristics, prevalence of APS, and clinical and analytical features of SLE and ALS between ethnic group.

The researchers found that the risk (odds ratio, 2.56; 95 percent confidence interval, 1.02 to 6.39) and prevalence of APS (28.8 versus 13.3 percent; P = 0.027) were increased in Roma SLE patients. They also had a higher prevalence of abortions (23.5 versus 10.2 percent; P = 0.049). A non-significantly higher prevalence of fetal deaths (14.3 versus 5.1 percent; P = 0.106) and thrombotic events (21.1 versus 12.2 percent; P = 0.160) was seen for Roma SLE patients. Roma patients had significantly higher prevalence of arthritis (75.0 versus 57.1 percent; P = 0.034), while the prevalence of serositis, discoid lesions, oral ulcers, and livedo reticularis were non-significantly higher (P = 0.104, 0.191, 0.218, and 0.374, respectively).

"Prevalence and risk of APS were significantly higher in Roma SLE patients," the authors write. "Furthermore, Roma patients had a significantly higher prevalence of abortions and a non-significant higher prevalence of fetal deaths and thrombotic events."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths